<DOC>
	<DOCNO>NCT00099047</DOCNO>
	<brief_summary>This randomized phase II trial study well celecoxib work prevent multiple myeloma patient monoclonal gammopathy smolder myeloma . Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use celecoxib may effective prevent multiple myeloma .</brief_summary>
	<brief_title>Celecoxib Preventing Multiple Myeloma Patients With Monoclonal Gammopathy Smoldering Myeloma</brief_title>
	<detailed_description>PRIMARY OJBECTIVES : I . Determine efficacy celecoxib v placebo reduce serum level M-component patient monoclonal gammopathy undetermined significance smolder myeloma . SECONDARY OBJECTIVES : I . Determine effect drug secondary biomarkers surrogate endpoint patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord participate center type monoclonal gammopathy ( monoclonal gammopathy undetermined significance v smolder myeloma ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive celecoxib orally ( PO ) twice daily ( BID ) 6 month absence unacceptable toxicity progression malignancy . ARM II : Patients receive placebo PO BID 6 month absence unacceptable toxicity progression malignancy . After completion study treatment , patient follow 1 , 6 , 12 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Criteria : Mprotein &gt; = 30 g/L No clinical evidence chronic infectious inflammatory disease No present evidence active malignancy ( nonmelanoma skin cancer cervical intraepithelial neoplasia allow ) No hypersensitivity ( e.g. , asthma , urticaria , acute rhinitis induce NSAIDs ) aspirin NSAIDs No hypersensitivity sulfonamides No uncontrolled diabetes No history diabetic retinopathy No condition would preclude study participation No condition would preclude use NSAIDs New preexist diagnosis 1 follow least 2 month : Monoclonal gammopathy undetermined significance define follow criterion : Mprotein = &lt; 30 g/L Bone marrow clonal plasma cell &lt; 10 % low level plasma cell infiltration trephine biopsy ( do ) Smoldering myeloma define least 1 follow criterion : Bone marrow clonal plasma cell &gt; = 10 % No related organ tissue impairment ( i.e. , end organ damage ) symptom Asymptomatic patient = &lt; 3 lytic lesion ( without organ damage ) attributable plasma cell dyscrasia allow No condition associate secondary monoclonal gammopathy IgG , IgA , light chain Mcomponent &gt; = 1.0 g/dL least 2 consecutive lab reading take least 4 week apart No anemia No hepatic insufficiency AST ALT &lt; 1.5 time upper limit normal ( ULN ) Bilirubin = &lt; 1.5 time ULN Creatinine = &lt; 1.8 mg/dL No hypercalcemia No renal insufficiency No uncontrolled congestive heart failure No history cerebrovascular cardiovascular accident No history gastrointestinal hemorrhage No active suspect peptic ulcer disease Previously treat H. pylori infection allow More 12 month since limited chemotherapy More 28 day since prior chronic frequent use glucocorticoid ( &gt; 5 mg prednisone equivalent per day ) More 28 day since prior chronic frequent use nonsteroidal antiinflammatory drug ( NSAIDs ) ( &gt; 100 mg aspirin per day ) More 28 day since prior bisphosphonate therapy More 28 day since prior investigational agent Concurrent lowdose aspirin ( = &lt; 100 mg/day ) allow No evidence Bcell proliferative disorder ( e.g. , multiple myeloma , Waldenstrom 's macroglobulinemia , primary amyloidosis , lymphoproliferative disease ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception AND/OR ECOG 01 Zubrod 01</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>